InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.
Read original at benzingaStocks · News reference
8-K filing — InMed Pharmaceuticals Inc. (INM)
Filed: 2026-07-22 AccNo: 0001213900-26-080414 Size: 303 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 22, 2026, 8:28 PM
- Checked
- Jul 22, 2026, 8:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading